Environmental phthalate and chronic kidney disease: Epidemiology, mechanistic pathways, and clinical implications.
文献摘要
Chronic kidney disease (CKD) remains a major global health problem, and early detection and risk control are still limited. Phthalates-widely used plasticizers with endocrine-disrupting effects-have been increasingly implicated in CKD-related outcomes. Human studies have reported associations between urinary phthalate metabolites and kidney-related markers, commonly reflected by the albumin-to-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR), although the direction and magnitude of these associations vary by metabolite, population, study design, and outcome definition. Mechanistic evidence is currently dominated by studies of di-(2-ethylhexyl) phthalate (DEHP) and its metabolite mono-(2-ethylhexyl) phthalate (MEHP), suggesting potential involvement of oxidative stress, inflammation, regulated cell death, epithelial-mesenchymal transition (EMT), and extracellular-matrix (ECM) remodeling in experimental models. However, the extent to which these mechanisms apply to other phthalates or alternative plasticizers remains uncertain. The evidence remains heterogeneous across populations and exposure contexts, and key limitations include its observational nature, exposure-measurement bias, reverse causality, and uncertainty regarding temporality and mixture effects. Future longitudinal, pharmacokinetic, and intervention studies are needed to determine whether phthalate biomarkers have clinically meaningful prognostic or predictive utility.